LRRK2 Volume Sensor Hijacking Drives Metabolic Dysregulation via SIRT1/PGC1α Suppression

Target: ? Composite Score: 0.559 Price: $0.56 Citation Quality: Pending neurodegeneration Status: proposed
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
⚠ No Target Gene⚠ Low Validation Senate Quality Gates →
Quality Report Card click to collapse
C+
Composite: 0.559
Top 25% of 654 hypotheses
T5 Contested
Contradicted by evidence, under dispute
C+ Mech. Plausibility 15% 0.55 Top 75%
C Evidence Strength 15% 0.42 Top 81%
B+ Novelty 12% 0.75 Top 56%
B Feasibility 12% 0.60 Top 49%
C+ Impact 12% 0.58 Top 83%
C+ Druggability 10% 0.52 Top 65%
B+ Safety Profile 8% 0.72 Top 30%
B Competition 6% 0.65 Top 64%
B+ Data Availability 5% 0.70 Top 40%
B Reproducibility 5% 0.68 Top 42%
Evidence
5 supporting | 4 opposing
Citation quality: 0%
Debates
1 session A+
Avg quality: 1.00
Convergence
0.00 F 30 related hypothesis share this target

From Analysis:

Does LRRK2's role as a lysosomal volume sensor explain the pathogenic mechanism of disease-linked LRRK2 mutations?

While the study establishes LRRK2 as a lysosomal swelling sensor and notes that lysosomal swelling occurs in LRRK2-linked diseases, it doesn't directly test whether pathogenic LRRK2 mutations alter this volume-sensing function. This connection is crucial for understanding how LRRK2 mutations cause Parkinson's disease and related disorders. Gap type: open_question Source paper: Lysosomal swelling triggers LRRK2 activity. (2026, bioRxiv : the preprint server for biology, PMID:41427358)

→ View full analysis & debate transcript

Description

Disease-linked LRRK2 mutations (G2019S, R1441C) cause excessive Rab phosphorylation during lysosomal swelling, creating a persistent 'volume sensing ON' state that chronically activates LRRK2 kinase. This hyperactivation consumes ATP and NAD+ pools, suppressing SIRT1 deacetylase activity and downstream PGC1α mitochondrial biogenesis. Restoring NAD+ via NAMPT activation or direct supplementation would rebalance metabolic setpoint.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.55 (15%) Evidence 0.42 (15%) Novelty 0.75 (12%) Feasibility 0.60 (12%) Impact 0.58 (12%) Druggability 0.52 (10%) Safety 0.72 (8%) Competition 0.65 (6%) Data Avail. 0.70 (5%) Reproducible 0.68 (5%) 0.559 composite
9 citations 9 with PMID Validation: 0% 5 supporting / 4 opposing
For (5)
No supporting evidence
No opposing evidence
(4) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
6
1
2
MECH 6CLIN 1GENE 2EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
LRRK2 at the crossroad of aging and PD shows age-d…SupportingMECH----PMID:33805527-
STRING shows LRRK2 functionally connected to SIRT1…SupportingMECH----PMID:NOSTRING-
LRRK2 mutations perturb lysosomal function leading…SupportingGENE----PMID:36085537-
VPS35 mutations induce LRRK2 hyperactivationSupportingGENE----PMID:38368930-
NAD+ decline with aging exacerbates LRRK2-PD patho…SupportingMECH----PMID:33805527-
The NADPARK phase I trial of nicotinamide riboside…OpposingCLIN----PMID:35235774-
While nicotinamide riboside rescued mitochondrial …OpposingMECH----PMID:29874584-
LRRK2 kinase activity phosphorylates Rab GTPases w…OpposingMECH----PMID:NOSTRING-
STRING enrichment score represents computational p…OpposingMECH----PMID:NOSTRING-
Legacy Card View — expandable citation cards

Supporting Evidence 5

LRRK2 at the crossroad of aging and PD shows age-dependent mitochondrial dysfunction
STRING shows LRRK2 functionally connected to SIRT1-PPARGC1A axis (score: 0.988)
LRRK2 mutations perturb lysosomal function leading to α-synuclein accumulation
VPS35 mutations induce LRRK2 hyperactivation
NAD+ decline with aging exacerbates LRRK2-PD pathogenesis

Opposing Evidence 4

The NADPARK phase I trial of nicotinamide riboside in PD patients showed safety but limited efficacy signals, …
The NADPARK phase I trial of nicotinamide riboside in PD patients showed safety but limited efficacy signals, suggesting NAD+ supplementation alone is insufficient for disease modification
While nicotinamide riboside rescued mitochondrial defects in iPSC and fly models, these were models of complex…
While nicotinamide riboside rescued mitochondrial defects in iPSC and fly models, these were models of complex I inhibition not LRRK2-specific
LRRK2 kinase activity phosphorylates Rab GTPases which is a low-energy reaction and would not substantially de…
LRRK2 kinase activity phosphorylates Rab GTPases which is a low-energy reaction and would not substantially deplete cellular NAD+ pools
STRING enrichment score represents computational prediction not experimental validation
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-16 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Mechanistically-Specific Hypotheses: LRRK2 Mutations and Lysosomal Volume Sensing

Hypothesis 1: Hyperactive Kinase Activity Amplifies Lysosomal Volume Signals in G2019S

Title: G2019S kinase hyperactivation amplifies volume-sensing output

Mechanism: The G2019S mutation in the LRRK2 activation loop increases basal kinase activity ~2-fold while preserving stimulus-induced activation. We propose that swollen lysosomes recruit LRRK2 via ARF GAP domains, but G2019S-LRRK2 exhibits exaggerated phosphorylation of downstream substrates (RAB10, RAB12, RAB29), creating a pathologica

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

Skeptic's Critical Evaluation

Hypothesis 1: G2019S kinase hyperactivation amplifies volume-sensing output

Strongest Specific Weakness: Conflation of baseline elevation with signal amplification

The hypothesis states that G2019S causes "exaggerated phosphorylation of downstream substrates" at swollen lysosomes, creating a "pathologically amplified signal." But the cited evidence (PMID: 25485882) shows elevated baseline RAB10-p, not amplified stimulus-evoked signal. These are mechanistically distinct phenomena. Elevated baseline could reflect:

  • A ceiling effect: G20
  • 🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

    Domain Expert Evaluation: LRRK2 Volume-Sensing Hypothesis

    Preliminary Framing Note

    The source paper concerns LRRK2 and Parkinson's disease biology, yet the query invokes an Alzheimer's clinical context. I will proceed by evaluating this hypothesis for neurodegenerative disease translation broadly, recognizing that LRRK2 mechanisms have implications across neurodegenerative proteinopathies. I will also address the obvious gap: there is only one hypothesis provided, so my assessment of "top 2-3" will necessarily address variations or extensions of Hypothesis 1.

    1. Trans

    Synthesizer Integrates perspectives and produces final ranked assessments

    {
    "ranked_hypotheses": [
    {
    "rank": 1,
    "title": "G2019S causes signal amplification, not baseline elevation, during acute lysosomal swelling",
    "mechanism": "G2019S-LRRK2 exhibits pathologically amplified kinase activation specifically upon acute swelling stimuli rather than elevated baseline activity, leading to RAB substrate hyperphosphorylation beyond physiological thresholds.",
    "target_gene": "LRRK2",
    "confidence_score": 0.65,
    "novelty_score": 0.7,
    "feasibility_score": 0.6,
    "impact_score": 0.85,
    "composite_score": 0.70,
    "tes

    Price History

    0.510.530.56 0.58 0.49 2026-04-162026-04-162026-04-16 Market PriceScoreevidencedebate 1 events
    7d Trend
    Stable
    7d Momentum
    ▲ 0.0%
    Volatility
    Low
    0.0000
    Events (7d)
    1

    Clinical Trials (0)

    No clinical trials data available

    📚 Cited Papers (6)

    Paper:29874584
    No extracted figures yet
    LRRK2 at the Crossroad of Aging and Parkinson's Disease.
    Genes (2021) · PMID:33805527
    No extracted figures yet
    Paper:35235774
    No extracted figures yet
    Paper:36085537
    No extracted figures yet
    Paper:38368930
    No extracted figures yet
    Paper:NOSTRING
    No extracted figures yet

    📓 Linked Notebooks (1)

    📓 Does LRRK2's role as a lysosomal volume sensor explain the pathogenic mechanism of disease-linked LRRK2 mutations? - Analysis Notebook
    CI-generated notebook stub for analysis SDA-2026-04-16-gap-pubmed-20260410-170027-a1e5f867. While the study establishes LRRK2 as a lysosomal swelling sensor and notes that lysosomal swelling occurs in …
    → Browse all notebooks

    ⚔ Arena Performance

    No arena matches recorded yet. Browse Arenas
    → Browse all arenas & tournaments

    Wiki Pages

    Alibaba Tongyi Qianwen-Bio (Chinese Biomedical LLMai_toolSIRT1 GenegeneNAMPT GenegeneLRRK2 — Leucine Rich Repeat Kinase 2gene

    Related Hypotheses

    TREM2-Dependent Microglial Senescence Transition
    Score: 0.736 | neurodegeneration
    SASP-Mediated Complement Cascade Amplification
    Score: 0.734 | neurodegeneration
    LRP1-Dependent Tau Uptake Disruption
    Score: 0.716 | neurodegeneration
    Nutrient-Sensing Epigenetic Circuit Reactivation
    Score: 0.700 | neurodegeneration
    Multi-Biomarker Composite Index Surpassing Amyloid PET for Treatment Response Prediction
    Score: 0.696 | neurodegeneration

    Estimated Development

    Estimated Cost
    $2M
    Timeline
    2.0 years

    🧪 Falsifiable Predictions

    No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

    Knowledge Subgraph (0 edges)

    No knowledge graph edges recorded

    Source Analysis

    Does LRRK2's role as a lysosomal volume sensor explain the pathogenic mechanism of disease-linked LRRK2 mutations?

    neurodegeneration | 2026-04-16 | completed